Aurobindo Pharma has decided to sell, transfer or otherwise dispose off its Unit-X, located at SIPCOT Industrial Complex, Village Kudikadu, Cuddalore in Tamil Nadu. The company is manufacturing some of the intermediates at the said unit.
The Unit was set up way back in the year 2002 and has not upgraded or expanded in the capacity as there are constraints for expansion within the same location. Further it is become unviable to manufacture those few intermediates as against directly procuring from others, now the operations have come to stand still.
The net block value of this unit as on March 31, 2012 was Rs 7.00 crore and it represents only 0.43% of total net block of fixed assets of the company.
Aurobindo Pharma’s net profit for the fourth quarter ended March 31, 2012 fell 33.70% to Rs 87.91 crore as compared to Rs 132.59 crore for the quarter ended March 31, 2011. However, the total income has increased by 3.51% to Rs 1100.41 crore for the quarter under review from Rs 1063.10 crore for the corresponding quarter of the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: